Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease
International Journal of Molecular Sciences · 27.09.2023 · 24 (19) · 14605
DOI: 10.3390/ijms241914605 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.09.2023. Verfasst von Paulina Vidal-Cevallos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Av. Puente de Piedra 150, Toriello Guerra, Tlalpan, Mexico City 14050, Mexico. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Thyroid Diseases, Hypothyroidism. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medica Sur Clinic and Foundation.
Abstract (Originalsprache)
The prevalence of hypothyroidism in patients with nonalcoholic fatty liver disease (NAFLD) is high (22.4%). Thyroid hormones (THs) regulate many metabolic activities in the liver by promoting the export and oxidation of lipids, as well as de novo lipogenesis. They also control hepatic insulin sensitivity and suppress hepatic gluconeogenesis. Because of its importance in lipid and carbohydrate metabolism, the involvement of thyroid dysfunction in the pathogenesis of NAFLD seems plausible. The mechanisms implicated in this relationship include high thyroid-stimulating hormone (TSH) levels, low TH levels, and chronic inflammation. The activity of the TH receptor (THR)-β in response to THs is essential in the pathogenesis of hypothyroidism-induced NAFLD. Therefore, an orally active selective liver THR-β agonist, Resmetirom (MGL-3196), was developed, and has been shown to reduce liver fat content, and as a secondary end point, to improve nonalcoholic steatohepatitis. The treatment of NAFLD with THR-β agonists seems quite promising, and other agonists are currently under development and investigation. This review aims to shine a light on the pathophysiological and epidemiological evidence regarding this relationship and the effect that treatment with THs and selective liver THR-β agonists have on hepatic lipid metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Av. Puente de Piedra 150, Toriello Guerra, Tlalpan, Mexico City 14050, Mexico.
ORCID-Profile: Sofía Murúa-Beltrán Gall, Norberto C Chávez-Tapia
Förderung
- Medica Sur Clinic and Foundation
Zitieren
APA
Vidal-Cevallos, P., Murúa-Beltrán Gall, S., Uribe, M., & Chávez-Tapia, N. C. (2023). Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease. International Journal of Molecular Sciences, 24(19), 14605. https://doi.org/10.3390/ijms241914605
Vancouver
Vidal-Cevallos P, Murúa-Beltrán Gall S, Uribe M, Chávez-Tapia NC. Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease. International Journal of Molecular Sciences. 2023;24(19):14605. doi:10.3390/ijms241914605
BibTeX
@article{VidalCevallos2023,
author = {Vidal-Cevallos, Paulina and Murúa-Beltrán Gall, Sofía and Uribe, Misael and Chávez-Tapia, Norberto C},
title = {Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {19},
pages = {14605},
doi = {10.3390/ijms241914605}
}
EUVIMED